Live cell detection of chromosome 2 deletion and Sfpi1/PU1 loss in radiation-induced mouse acute myeloid leukaemia  by Olme, C.-H. et al.
L
r
C
B
a
A
R
R
A
A
K
R
L
C
S
M
M
1
E
s
v
t
a
f
i
A
k
u
m
a
E
r
f
0
hLeukemia Research 37 (2013) 1374– 1382
Contents lists available at ScienceDirect
Leukemia  Research
journa l h o me  pag e: www.elsev ier .com/ locate / leukres
ive  cell  detection  of  chromosome  2  deletion  and  Sfpi1/PU1  loss  in
adiation-induced  mouse  acute  myeloid  leukaemia
.-H.  Olme,  R.  Finnon,  N.  Brown,  S.  Kabacik,  S.D.  Boufﬂer,  C.  Badie ∗
iological Effects Department, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Chilton, Didcot, Oxfordshire, UK
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 21 February 2013
eceived  in revised form 24 May  2013
ccepted 26 May  2013
vailable online 25 June 2013
eywords:
adiation
a  b  s  t  r  a  c  t
The  CBA/H  mouse  model  of  radiation-induced  acute  myeloid  leukaemia  (rAML)  has  been  studied  for
decades  to  bring  to  light  the  molecular  mechanisms  associated  with  multistage  carcinogenesis.  A  speciﬁc
interstitial  deletion  of  chromosome  2 found  in  a  high  proportion  of  rAML  is  recognised  as  the  initiating
event.  The  deletion  leads  to the  loss  of  Sfpi,  a  gene  essential  for haematopoietic  development.  Its  product,
the  transcription  factor  PU.1  acts  as  a tumour  suppressor  in  this  model.  Although  the  deletion  can  be
detected  early  following  ionising  radiation  exposure  by  cytogenetic  techniques,  precise  characterisation
of  the  haematopoietic  cells carrying  the  deletion  and  the  study  of their  fate  in  vivo  cannot  be  achieved.ive cells
hromosome deletion
fpi1/PU.1
yeloid  leukaemia
ouse  model
Here,  using  a  genetically  engineered  C57BL/6  mouse  model  expressing  the  GFP  ﬂuorescent  molecule
under  the  control  of  the Sfpi1  promoter,  which  we  have  bred  onto  the  rAML-susceptible  CBA/H  strain,  we
demonstrate  that  GFP  expression  did  not  interfere  with  X-ray  induced  leukaemia  incidence  and  that  GFP
ﬂuorescence  in  live  leukaemic  cells  is a surrogate  marker  of  radiation-induced  chromosome  2  deletions
with  or without  point  mutations  on  the remaining  allele  of  the  Sfpi1  gene.  This  study  presents  the  ﬁrst
experimental  evidence  for  the  detection  of  this  leukaemia  initiating  event  in  live  leukemic  cells.
 201  ©
. Background
Ionising radiation (IR) is a well known carcinogen in humans.
pidemiological studies of mortality and incidence of cancer have
hown an increased risk of cancer in the Japanese atomic bomb sur-
ivors, in those exposed to ionising radiation therapeutically and in
he nuclear industry workers [1–4]. In survivors of the Hiroshima
nd Nagasaki atomic bombs, an excess risk in solid cancers was
ound and an approximately 5-fold increase in leukaemias, includ-
ng acute lymphocytic leukaemia, chronic myeloid leukaemia and
ML was seen [5]. However, formal identiﬁcation of human cancers
nown to be caused speciﬁcally by radiation exposure remains an
nsolved issue and there is no comprehensive understanding of the
olecular mechanisms of cancer induction by IR.
Animal models of human cancers are extremely valuable for
 better understanding of the molecular mechanisms of tumour
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initiation and development, in particular for cancers induced by
environmental agents such as IR. rAML is one IR induced tumour
for which mouse models are available. The CBA model of rAML, has
been used for over 30 years to study rAML [6]. It is a particularly
valuable model due to the very low spontaneous AML  incidence
[7]. A single whole-body exposure of X-rays at a dose of 3 gray gave
maximal yields around 25% [6]. In the mice that develop rAML, it
has been found that over 90% of the leukaemic blasts have a partial
deletion of one copy of chromosome 2 in CBA/H mice and other
strains susceptible to the disease [7–11]. Chromosome 2 intersti-
tial deletions (Del2) are characteristic of rAML [12]. Cells carrying
the chromosome deletion start to expand clonally in 50% of the
animals around 12 months after radiation exposure, probably due
to a proliferative or selective advantage, but ultimately up to only
25% of the mice are diagnosed with rAML suggesting that other
molecular events arising spontaneously are required for AML  devel-
opment [6,13]. Del2 can be seen in bone marrow from all CBA/H
mice irradiated with a whole-body dose of 3 Gy 24 h after expo-
sure and although this early chromosome deletion does not lead
directly to rAML in all mice, this event is considered the initiat-
ing molecular event that potentially leads to leukaemia [13,14].
The key gene identiﬁed in the deleted region is Sfpi1 coding for
Open access under CC BY-NC-ND license.the haematopoietic transcription factor PU.1 [15–18]. Sfpi1 suffers
from point mutation in exon 5, the DNA binding domain, following
hemizygous loss in approximately 70% rAMLs [11,15,16]. Transcrip-
tional expression levels of Sfpi1 and PU.1 protein expression, have
e. 
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een shown in several cases to be important for the maturation
nd differentiation of haematopoietic cells [19,20]. Importantly,
eduction to about 20% of normal levels of the gene or conditional
omplete inactivation in vivo were found to lead to the develop-
ent of AML  [21,22]. Some cases of rAML do not have Sfpi1 deletions
r point mutations and recently we have reported internal tandem
uplications in Flt3 (the most common mutation in human AML)
ithin a panel of rAMLs [23]. An inverse relationship between the
xpression of the gene Flt3 and Sfpi1 has also been observed [24,25].
Currently, Del2 are detected using PCR based loss of heterozy-
osity in F1 hybrid mice and ﬂuorescence in situ hybridisation
FISH) techniques [14,26,27]. However, these are respectively
erformed on DNA extracts and ﬁxed cells limiting further char-
cterisation. Fundamental questions on the biology of this deletion
emain unresolved because of the difﬁculty in detecting individ-
al Del2-bearing cells in vivo. Transgenic mouse models expressing
reen ﬂuorescent protein (GFP) as a reporter gene for Sfpi1 expres-
ion have been created by two separate research groups to make
ossible the monitoring of Sfpi1 expression during hematopoiesis
nd the development of subpopulations of bone marrow cells
28,29]. Here, we made use of Nutt et al. engineered mouse model
y transferring it onto the CBA/H genetic background, postulating
hat it would be possible to use the GFP expression marker to iden-
ify radiation-induced Del2 ex vivo. This study presents the ﬁrst
xperimental evidence for the detection of copy loss of Sfpi1 and
U.1 expression in live leukaemic cells.
. Methods
.1. Mice
C57BL/6 GFP expressing mice from Steven Nutt were re-derived and backcrossed
o  a CBA/H background at MRC  for at least 10 generations for all experiments (Har-
ell, Oxon, UK) [28,30]. The GFP construct is situated in the 3′ untranslated region
f  the Sfpi1 gene, located on mouse chromosome 2 where GFP is under the control of
he Sfpi1 promoter. During transcription a bicistronic mRNA is produced, generating
ild-type PU.1 protein and GFP.
Both CBA/H Sfpi1GFP/GFP and CBA/H Sfpi1GFP/+ animals (generated from a homozy-
ous  male and wild type CBA/H female) were utilised in this study. All animals were
red and handled according to UK Home Ofﬁce Animals (Scientiﬁc Procedures) Act
986 and with guidance from the local ethical review committee on animal exper-
ments. Details of the original construct, its localisation on mouse chromosome 2
nd position of primers used for genotyping are presented in Fig. 1.
.2. rAML induction experiment
50  male Sfpi1GFP/+, 50 male Sfpi1GFP/GFP and 15 female Sfpi1GFP/GFP mice were
hole-body 3 Gy irradiated at 12–15 weeks of age with 250 kVp X-rays at a dose
ate of 0.887 Gy/min (MRC Radiation and Genome Stability Unit, Harwell, Oxon,
K).  AMLs were diagnosed using the criteria described in the Bethesda Proposals
or  Classiﬁcation of Non-Lymphoid Neoplasms in mice [31]. Mice were examined
aily  for signs of illness and euthanised with a rising concentration of CO2. Animals
ound to have increased white blood cell counts in the peripheral blood ﬁlm and
isplaying splenomegaly or hepatosplenomegaly upon dissection were treated as
otential AMLs. Samples of spleen were either stored at −70 ◦C in RNAlater (Ambion,
ustin, US) for nucleic acid extraction or disaggregated and used for FACS or chro-
osome preparations for cytogenetics. All cases deﬁned as AML had a rapid onset,
ith ≥20% immature forms/blasts found when spleen cell samples were analysed by
ow cytometry, and a white blood cell count above that of controls (controls: approx.
–10 × 106/mL). Flow cytometry analysis (as performed below) furthermore estab-
ished that cases of AML  are further deﬁned by the surface marker expression as
escribed in the text.
.3.  Flow cytometry phenotyping of rAML cases
1 × 105 cells were incubated with Fc Block (BD Bioscience), aside from samples
tained  with antibodies against FcRIII/II. After transfer to a fresh tube, the following
rimary  antibodies were added (all diluted in PBS/3% BSA), according to manu-
acturer’s  recommendations: Gr-1/Ly6G-PE (clone 1A8), CD31-PE, CD3-PE, Flt3-PE
BD Bioscience), Mac-1-PE/Cy5, Ly6C-PE, c-kit-PE, B220 (CD45R)-PE/Cy5, CD34-PE,
D38-PE, VCAM1-PE, Thy-1-PE, FcRIII/II-PE (Abcam, Cambridge), c-kit-PE/Cy5 and
ca-1-PE (Biolegend, CA USA). Samples were analysed on a FACS Calibur (BD Bio-
cience) ﬂow cytometer using CellQuest software. Regions were drawn around
ajor  populations of cells on a FSC/SSC dot plot. Events with low FSC/SSC were
ssumed  to be dead cells and debris, and excluded from analysis [32]. Analysis wasrch 37 (2013) 1374– 1382 1375
performed on cells with high FSC/SSC. The GFP geometric mean ﬂuorescence inten-
sity (geo MFI) of samples was  determined by the mean channel number on a log
scale  x-axis on a histogram or on the lower right quadrant on a dot plot. In exper-
iments  where indicated in the text, 7-Aminoactinomycin D (7-AAD) (Sigma) was
added, 5 l/sample.
2.4. PCR and qPCR
To determine Sfpi1/GFP construct copy number in rAML and control spleen cells
and ear-clip DNA for genotyping, duplex PCR using the following genotyping primers
(Sigma) were used:
Forward A-5′ TGGCGCCTACCGGTGGATGTGG 3′
Reverse B-5′ CTGTGTGCCACCACCTGCCTACATT 3′
Forward C-5′ GTGCTTCTTTGGGAGTCTGGCGCT 3′
Primer A and B identiﬁes the 512 base pair (bp) Sfpi1/GFP allele and primer B
and  C identiﬁes the 680 bp wild type Sfpi1 allele.
To  determine the amount of contaminating normal DNA that could be toler-
ated  in the copy number anaylsis of rAMLs, standard mixes of normal splenocyte to
leukaemic DNA were used (9:1, 7:3, 1:1, 3:7, 1:9) [33].
Samples (25 ng/l) were run on a Hybaid PCR express thermocycler (4 min at
95 ◦C, 45 cycles of 15 s each at 95 ◦C, 55 ◦C and 72 ◦C, and a 10 min at 72 ◦C). Products
were  analysed using a 2% agarose gel (BioRad, Hercules, US), stained with ethidium
bromide and visualised using UV on a BioRad Gel Doc 2000 system.
For  qPCR, reactions were performed as previously described [34,35]. Primer and
probe sets used (Eurogentec Ltd., Fawley, Hampshire, UK)  are as follows:
Sfpi1  (forward) 5′ AGAAGCTGATGGCTTGGAGC 3′
Sfpi1 (reverse) 5′ GCGAATCTTTTTCTTGCTGCC 3′
6-Hexachloroﬂuorescein 5′ TGGGCCAGGTCTTCTGCACGG 3′
GFP (forward) 5′ AGCCGCTACCCCGACCACAT 3′
GFP (reverse) 5′ CGGTTCACCAGGGTGTCGCC 3′
Texas Red 5′ GCCCGAAGGCTACGTCCAGGAGCGC 3′
HPRT (forward) 5′ GGACAGGACTGAAAGACTTG 3′
HPRT (reverse) 5′ TAATCCAGCAGGTCAGCAAA 3′
6-Carboxyﬂuorescein 5′ CCCTTGAGCACACAGAGGGCCACA 3′ .
Gene target cycle threshold (Ct) values were normalised to a hypoxanthine
guanine  phosphoribosyl transferase (Hprt) internal control and were converted to
transcript quantity (SQ) using standard curves run with each qPCR plate.
2.5. DNA sequencing and analysis of point mutations
Exon 5 mutations in Sfpi1 were determined by DNA sequencing as
described  [16,25] using primer sequences: F-5′CGACATGAAGGACAGCATCT3′ and
R-5′TTTCTTCACCTCGCCTGTCT3′ (Sigma).
2.6. Fluorescent in situ hybridisation (FISH)
2.6.1. Chromosome preparations
Disaggregated spleen cells were cultured at a concentration of
1.5–2  × 106 cells/mL in 5 mL IMDM/20% FBS, 100 U/mL Penicillin and 100 g/mL
Streptomycin  (Fisher Scientiﬁc) with addition of 25 g/mL lipopolysaccharide
(Sigma) and 4 g/mL ConcavalinA (Amersham Biosciences, UK) for 48 h. Colcemid
was  added at 0.6 g/mL and incubated for 1 h. After a 15 min  hypotonic treatment
(0.075  M KCl at 37 ◦C), cells were ﬁxed (1:3 acetic acid/methanol) and stored at
−20 ◦C until slide preparations.
2.6.2. Bacterial artiﬁcial chromosome (BAC) probes and FISH
BAC probes and the FISH technique was carried out on ﬁxed splenocytes using
the protocol described [14].
2.7. Statistical analysis
Where statistical analysis has been performed, this was  done by a 1-tailed,
unpaired  Student’s t-test using Microsoft Excel.
3. Results
3.1. Effect of GFP reporter gene on susceptibility of mice to
radiation-induced AMLIn  order to evaluate whether the GFP cassette would affect the
incidence of rAML a total of 115 mice, 50 male Sfpi1/GFP het-
erozygous (Sfpi1GFP/+), 50 Sfpi1/GFP homozygous (Sfpi1GFP/GFP) and
1376 C.-H.  Olme et al. / Leukemia Research 37 (2013) 1374– 1382
Fig. 1. Location of the GFP construct and a detailed view of the some of its features. The GFP construct is situated in the 3′ untranslated region of the Sfpi1 gene, located on
mouse chromosome 2. The Sfpi1 gene is located in the AML  minimal deleted region (mdr) 
coding  region in grey and introns as a black line, where exon 5 is speciﬁcally denoted. The
A,  reverse B and forward C are indicated. Stop: Stop codon, IRES: internal ribosome entry
Fig. 2. Leukaemia incidence. Kaplan–Meier analysis of cumulative probability of
radiation-induced acute myeloid leukaemia in male CBA/H (total number irra-
diated = 57, AML  induced = 9) and CBA GFP mice (total number irradiated = 100,
AML  induced = 18) following 3 gray acute whole body X-irradiation. For GFP AMLs,
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bfpi1GFP/+ individual AMLs are represented by a white circle and Sfpi1GFP/GFP by a grey
ircle.  No signiﬁcant difference in rAML latency or penetrance was  found between
BA  and CBA GFP AMLs (log rank p = 0.712).
 further 15 Sfpi1GFP/GFP female mice were irradiated with 3 Gy X-
ays at 12–15 weeks of age. Previous AML  induction experiments
ithin our laboratory (data unpublished) and at other institutions
n the last 5 years have seen AML  incidences of approximately 16%
n male CBA mice. Here we report a similar incidence of 18% in male
fpi1GFP (i.e. Sfpi1GFP/+ and Sfpi1GFP/GFP) mice, all of which arose in
he same window of time; 38–89 weeks (Fig. 2). Only one female
about 7%) out of 15 was diagnosed with AML  and this is consistent
ith previous work describing a lower incidence in CBA/H [36,37].
.2. Analysis of GFP expression levels in mice by ﬂow cytometry
GFP  expression in bone marrow cells from Sfpi1GFP/+ and
omozygote Sfpi1GFP/GFP mice was analysed by ﬂow cytometry.
ontrol non-GFP mice were used to estimate the level of auto-
uorescence with apoptotic 7-AAD positive cells being excluded
Fig. 3A). The expression of GFP can be divided into three levels
ased on the three discrete populations of ﬂuorescence intensity:between D2Mit126 and D2Mit185. Exons of the gene are denoted as boxes with the
 direction of transcription is marked by arrows. Three primer binding sites forward
 site, Neo: neomycin cassette.
GFP  negative/low, GFP medium and GFP high (Fig. 3B). The percent-
age of GFP expressing cells in bone marrow is similar between the
Sfpi1GFP/+ and Sfpi1GFP/GFP mice in each level, 15% and 17% (GFP low),
and 26% and 31% (GFP high). Overlaying histograms for Sfpi1GFP/+
and Sfpi1GFP/GFP mice shows that GFP expression in heterozygotes
is close to 50% of that in homozygote mice.
Examination of RNA levels of Sfpi1 and GFP by quantitative poly-
merase chain reaction (qPCR) showed a good correlation between
the levels of GFP mRNA and the copy number of the construct
(Fig. 3C) with Sfpi1GFP/GFP mice having around double the amount
of GFP mRNA compared to Sfpi1GFP/+ mice (mean 1.0 and 0.54
respectively, p = 0.000004) thus conﬁrming that GFP expression is
a sensitive surrogate of Sfpi1 expression.
3.3. Phenotyping of rAML cases using ﬂow cytometry
Immunophenotyping was carried out on all suspected rAML
cases using an antibody panel based on published recommen-
dations [31,38]. The major populations of cells were gated on a
forward scatter (FSC)/side scatter (SSC) dot plot. GFP expression
was analysed on an unstained sample and the percentage positive
cells obtained from percentage events in the GFP single positive
quadrant of a dot plot. The geometric mean ﬂuorescence inten-
sity was  determined from the same quadrant. Percentage positive
cells for a speciﬁc surface marker were obtained by combining the
percentage of the two upper quadrants in the dot plot.
All  rAML cases are negative for the two lymphoid markers CD3
and B220 and for CD38, apart from 57.3b (Supplementary Table 1),
which we believe has a mixed-lineage leukaemia phenotype. Fur-
thermore the phenotype was  CD34 negative, positive for myeloid
markers Mac-1, FcRIII/II, CD31 and Ly6C, and positive for the stem
cell marker c-Kit with a variable expression of Gr-1, Sca-1, Flt3,
VCAM-1 and Thy-1 (Fig. 4B and Supplementary Table 1). This sug-
gests an immunophenotype of acute monocytic leukaemias with a
variable granulocytic component, and a single bi-phenotypic case.
The detailed surface marker expression of a panel of 9 samples can
be seen in supplementary Table 1. Differential cell counts, neu-
tropenia and blast cell morphology in blood ﬁlms conﬁrm this
diagnosis of a monocytic lineage.
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Fig. 3. The correlation between GFP expression and Sfpi1 expression. (A) Bone marrow cells were extracted from femora and tibias, washed in PBS and analysed by ﬂow
cytometry with the addition of 7-AAD. A region was set around the major populations on a forward/side scatter plot and a gate was set on the 7-AAD negative population.
The expression of GFP was  analysed in the FL1 channel on a FACS Calibur ﬂow cytometer. (B) The GFP expression in Sfpi1GFP/+ and Sfpi1GFP/GFP mice was  analysed by ﬂow
cytometry as above. Markers show the GFPmedium and GFPhigh regions and numbers denote percentages of positive cells. In the overlay ﬁgure, Sfpi1GFP/+ samples are shown by
a f 3–5 
a T-PCR
t he mR
f
2
3
t dashed line and Sfpi1GFP/GFP samples by a continuous line. Data is representative o
nd methods and the mRNA expression levels of GFP and Sfpi1 were analysed by qR
riplicate samples. A Student’s t-test was used to test the statistical signiﬁcance of t
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.leukres.
013.05.019..4.  Identiﬁcation of Sfpi1 copy loss in live leukemic cells
GFP  expression in rAML cells was analysed by ﬂow cytome-
ry with 3 cases showing a negative/low expression (52.1f, 61.2f,mice. (C) RNA was  extracted from total bone marrow cells as described in material
. mRNA levels were normalised to Hprt. Error bars show the standard deviation in
NA levels in Sfpi1GFP/+ and Sfpi1GFP/GFP mice (p = 0.000004).
51.1c),  3 cases a medium expression (61.3d, 62.2d, 57.3b) and 3
cases a high GFP expression (58.2c, 58.1f, 61.2g) (Fig. 5A).
Knowing  that it is possible to distinguish between WT and
Sfpi1GFP by PCR with primers speciﬁc for exon 5 in Sfpi1 and the GFP
construct, we  expected to be able to detect deletions on chromo-
some 2 [28,30]. Wild type Sfpi1 gives a product of 680 bp, whereas
Sfpi1GFP/+ gives a product of 690 bp and 512 bp. For Sfpi1GFP/GFP mice
carrying two copies of the GFP construct (i.e. 512 bp product), the
PCR assay cannot be used to detect deletions of one copy. DNA was
1378 C.-H.  Olme et al. / Leukemia Research 37 (2013) 1374– 1382
Fig. 4. Immunophenotyping of rAML cases. Single cell suspensions were made of spleen tissue from rAML cases. Cells were stained with ﬂuorescent antibodies speciﬁc for
various surface markers and analysed by ﬂow cytometry. (A) A gate was drawn around a blast like population with high forward and side scatter, not present in control
spleen. Plots were then analysed on a dot plot for GFP expression and a surface marker. (B) Dot plots gated as above for surface markers. Myeloid markers (Gr-1, Mac-1, CD31,
Ly6C,  FcR II/II and VCAM-1), T- and B-cell markers (CD3 and B220), myeloid progenitor and haematopoeitic stem cell markers (c-Kit, Sca-1, CD34, CD38, Flt3 and Thy-1).
C.-H. Olme et al. / Leukemia Research 37 (2013) 1374– 1382 1379
Fig. 5. (A) GFP expression in rAML cases analysed by ﬂow cytometry. The GFP expression in rAML cases displayed in an overlay histogram. On the right hand side, genotype,
case name, type of point mutation is labelled. In Sfpi1GFP/+ mice, whether the GFP allele is lost or retained is noted. (B) PCR genotyping of rAML cases. DNA was extracted
from spleen material of control mice (CBA WT,  CBA Sfpi1GFP+/− and CBA Sfpi1GFP+/+) and rAML cases. PCR duplex reactions were set up amplifying the region containing the
GFP construct and the products were analysed on an agarose gel. WT  – 680 bp, Sfpi1GFP/GFP – 512 bp, Sfpi1GFP/+ – 680 bp and 512 bp products respectively. A mix  of known
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boncentrations  of WT and Sfpi1GFP+/+ DNA was used to estimate potential contamin
ase names and colour coding is consistent with Fig. 4A. Stars denotes cases with p
xtracted from spleen material of CBA/H, Sfpi1GFP/+ and Sfpi1GFP/GFP
ontrol mice as well as 9 rAML cases presented (Fig. 5B).
Two  of the Sfpi1GFP/+ mice (61.3d and 61.2g) showed an
mbalance in the bands that is similar to that seen in the 1:9
T/Sfpi1GFP/GFP standard. 3 mice (52.1f, 61.2f and 51.1c) showed an
mbalance in the bands similar to the 9:1 WT/Sfpi1GFP/GFP standard.
hen the cases were grouped according to whether they showed
FP positivity by ﬂow cytometry analysis, it became clear that the
mbalance likely indicated a loss of one allele of Sfpi1. The case 61.2g
nd 61.3d were conﬁrmed by FISH to have lost the WT  allele of
fpi1 (data not shown). The case that was weakly positive for GFP
y ﬂow cytometry analysis, but showed a normal Sfpi1GFP/+ geno-
ype (62.2d) as assessed by PCR, was conﬁrmed by FISH to be a
ase where no deletion of Sfpi1 could be detected. All three cases
hat were GFP negative by ﬂow cytometry analysis (52.1f, 61.2f
nd 51.1c) had a majority ampliﬁcation of the WT allele and were
onﬁrmed by FISH to have lost a copy of Sfpi1.
The loss of GFP expression assessed by ﬂow cytometry in
fpi1GFP/+ mice correlates with the PCR veriﬁcation of GFP allele
oss. Sfpi1GFP/+ mice without a loss of a Sfpi1 allele retain a medium
FP expression and the expected Sfpi1GFP/+ PCR products with two
ands. Sfpi1GFP/+ mice that have lost the non-GFP carrying allele ofof spleen tissue. From left to right (parts WT/Sfpi1GFP/GFP) 9:1. 7:3, 1:1, 3:7, 1:9. The
utations. FACS+ve: GFP positive, FACS−ve: GFP negative.
Sfpi1  show GFP expression as measured by ﬂow cytometry and the
PCR product is that expected from a Sfpi1GFP/GFP mouse. FISH was
used to conﬁrm all copy loss, which veriﬁed results from the ﬂow
cytometry and PCR genotyping. In particular, FISH was necessary to
conﬁrm Sfpi1 copy loss in Sfpi1GFP/GFP mice where PCR genotyping
could not be used (cases 58.2C, 58.1f and 57.3b).
A clear signiﬁcant correlation between the geometric mean of
GFP expression and GFP copy number was obtained in unirradiated
BM cells from mice with either 0, 1 or two  GFP copies (p = 0.0324)
and in rAML Sfpi1GFP/+ cases (p = 0.008), thus demonstrating that
the expression level of GFP in Sfpi1GFP/+ rAMLs is depending on the
GFP copy being retained or not (Supplementary Fig. 1).
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.leukres.
2013.05.019.
Six  of the rAMLs analysed in this study have retained a Sfpi1 GFP
allele. Interestingly, 58.2c, 58.1f and 61.2g carry a transition type
point mutation G:A in exon 5 of the remaining copy of Sfpi1 (where
the amino-acid R235 is changed to Histidine, codon CGC to CAC)
and express higher levels of GFP (geometric mean of 130, 80 and
78 respectively) whereas rAMLS 61.3d, 62.2d and 57.3b (geometric
mean of 50, 31 and 37 respectively) have no point mutation in Sfpi1.
1380 C.-H.  Olme et al. / Leukemia Research 37 (2013) 1374– 1382
Fig. 6. The expression of Sfpi1 in rAMl cases. RNA was  extracted from rAML spleen cases and the mRNA expression analysed by multiplex-quantitative PCR. Samples were
run in triplicate and Ct values were ﬁrst normalised to the reference gene Hprt and converted to transcript quantity using a standard curve. The mRNA expression is shown
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ubstitution. White: Wild type Sfpi1 allele. The case names are shown below each b
ean of two independent repeats using two different spleen samples. Error bars re
he identiﬁcation of speciﬁc mutations in the DNA binding domain
f PU.1 in exon 5 (position R235) are presented in Supplementary
able 1.
.5.  Lower Sfpi1 transcriptional expression in rAMLs without a
oint  mutation in Sfpi1 exon 5
Sfpi1 transcriptional expression in leukaemic inﬁltrated spleen
ells was analysed by qPCR. Results showed that the level of mRNA
xpression in rAMLs with a point mutation is relatively close to
hat in the control tissue, mouse bone marrow from non-rAML mice
Fig. 6). This suggests that the level of mutated RNA has not been
odiﬁed during leukaemogenesis. In contrast, in rAMLs without
 Sfpi1 point mutation (51.1c, 61.3d, 62.2d and 57.3b), leukaemic
ells have a lower transcriptional expression of Sfpi1.
.  Discussion
IR is a carcinogen that is able to initiate and promote neoplastic
evelopment. Experimental investigation of the induction of pre-
alignant growths and tumours in laboratory animals exposed
o IR has allowed insights into the mechanisms of radiation car-
inogenesis, from which better understanding of cancer in humans
an be achieved. Technological advances in engineering the mouse
enome with chromosome translocations, tissue-speciﬁc and/or
emporally regulated mutations have provided models which bet-
er mimic  human cancer [39].
Engineering chromosomal rearrangements in mice using a com-
ination of gene-targeting techniques in mouse embryonic stem
ells and the Cre/loxP site-speciﬁc recombination system allow
he modelling of human diseases that are associated with chro-
osomal aberrations [40,41]. IR is an efﬁcient clastogen and at
ufﬁciently high doses, chromosome deletions and other chromo-
ome rearrangements are lethal for cells. Nevertheless, it remains
ncertain that a chromosome aberration is the key initiation event
n radiation carcinogenesis. No speciﬁc chromosomal aberrations
ave been conﬁrmed as the rate-limiting event [42]. This makes
t difﬁcult to engineer speciﬁc chromosomal rearrangements in
ice to mimic  radiation-induced cancer. The strongest evidence
or a tumour-initiating radiation-induced aberration comes from
AML in CBA mice. Taking advantage of the over-representation
f chromosome 2 aberrations in BM cells following IR exposure,
ore speciﬁcally the interstitial deletion (minimal deleted region:
2Mit126 to D2Mit185 representing a chromosome fragment ofed according to the point mutation status. Black: R235H substitution. Grey: R235C
 the chart and del2 indicates cases carrying copy loss of Sfpi1. The results show the
t the standard deviation between independent experiments.
21 Mbp), we postulated that the loss of this chromosome frag-
ment carrying a GFP cassette placed next to the Sfpi1 gene (sfpi1
exon 5 internal ribosome entry site (IRES) GFP cassette) would be
detectable by assessing the decrease (CBA/H Sfpi1GFP/GFP) or loss
(CBA/H Sfpi1GFP/+) of GFP ﬂuorescence [12]. We  made use of an engi-
neered mouse model to identify these interstitial deletions ex vivo
in live leukemic cells by ﬂow-cytometry. Flow cytometry and cell
sorting are regularly used to analyse and acquire speciﬁc cell popu-
lations allowing the study of cells carrying ﬂuorescence emitting
reporter genes for speciﬁc genes of interest. Signiﬁcant improve-
ment in the quality of DNA content analysis have been made; high
resolution cell cycle proﬁles and ploidy alterations (DNA-indices
as small as 1.09) can be now detected in tumour samples [43].
Flow karyotyping (analysis of chromosomes in suspension by ﬂow-
cytometry) can be used to detect chromosomal rearangements and
speciﬁc repetitive DNA sequences [44]. Nevertheless, due to tech-
nical limitations, chromosomal deletions cannot be detected in
individual live cells. Takizawa et al. developed a genetic system
for the detection of T(12;15) (Igh-Myc) translocations in plasma
cells of a mouse strain in which an enhanced GFP-encoding reporter
gene has been targeted to Myc  providing a proof of principle that
chromosomal aberration can be detected in vivo [45]. Here, we
have developed a genetic method for the detection of individual
chr2del-carrying cells in mice diagnosed with rAML.
We  acquired a transgenic mouse model expressing GFP under
the Sfpi1/PU.1 promoter, and backcrossed it to the CBA/H strain for
the use for our purposes [28,30]. In our hands, the GFP expres-
sion levels showed a similar proﬁle to the original model with
T-cells being negative for GFP expression, B-cells expressing GFP
at negative/low levels and myeloid cells such as monocytes and
macrophages at high levels (data not shown) [30]. The expression
level of GFP protein in the GFP-mouse model was previously shown
to be comparable to the level of PU.1 protein and also to have a
similar half-life, as assessed by western blotting [28].
We  ﬁrst demonstrated that the introduction of the GFP construct
affected neither the genetic susceptibility of mice to radiation-
induced AML  development nor its time to onset. In these exposed
mice diagnosed with rAML, it was  possible to look at GFP expres-
sion, indicative of Sfpi1 expression, in individual leukaemic cells in
combination with surface marker antibody staining. As in humans,
the immunophenotyping of suspected leukaemia cases aids clas-
siﬁcation of the leukaemia type. In general, individual surface
marker expression of the spleen inﬁltrating blasts showed rel-
atively heterogeneous expression levels between cases, but a
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ommon phenotype was possible to determine (CD31, Ly6c, c-
it, Mac-1, FcRIII/II positive, Sca-1, Gr-1, VCAM-1 variable, and
D3, B220, CD34 negative), excluding two cases of biphenotypic
eukaemia that were B220+ CD31low and CD38high. Hirouchi and
olleagues recently reported their ﬁndings of a common myeloid
rogenitor – like leukaemic stem cell (LSC) (Lin− Sca-1− c-Kit+
D34+) in the C3H/He model of rAML [46]. In contrast, in the CBA/H
ases presented here, CD34 is generally not expressed. Therefore,
 slightly different phenotype may  be deﬁned as a LSC for rAML in
he CBA/H strain and further work needs to be done to investigate
nd conﬁrm this.
The  reduction of GFP expression in the Sfpi1GFP/+ mice with a
opy loss of Sfpi1 on the allele carrying the GFP construct was
onsistent and conﬁrmed by genotyping PCR and FISH. This pro-
ides proof of principle that the model can be used to detect partial
eletions of chromosome 2.
Furthermore, in the small set of rAMLs studied here, the level
f residual GFP expression seems to give a very good indication of
he status of the remaining Sfpi1 allele; remarkably, the detection
f the ﬂuorescence level in live leukaemic cells by ﬂow cytometry
eems sensitive enough to indicate the presence of a point muta-
ion in the gene, indicating that Sfpi1/PU.1 level is probably tightly
egulated in leukaemic cells. The affected amino-acid in rAMLs car-
ying a point mutation corresponds to R235 which is an integral
omponent of the ETS domain and so DNA binding of the pro-
ein [47]. The structure of the wild type and mutant amino acid
esidues differ signiﬁcantly and consequently probably modify the
rotein conformation, inﬂuencing the function of the ETS domain
or DNA recognition and binding thus impairing PU.1 role as tran-
cription factor. R235H may  lead to a totally non-functional protein
hile PU.1 protein carrying R235C might keep some functionality
xplaining why  it is repressed at the transcriptional level.
In  rAMLs where no deletion mutation occurs, the level of PU.1
as to be kept at very low level in cells to avoid differentiation.
he mRNA levels in these leukaemic cells suggest that the repres-
ion of expression is occurring at the transcriptional levels probably
hrough epigenetic mechanisms.
These results not only provide for a simpliﬁcation of analysing
he deletion status of chromosome 2 in the rAML cases, but also
uggest that it might be possible to select and sort by FACS speciﬁc
ubpopulations of cells carrying this deletion at earlier stages in the
eukaemic process, long before the presentation of rAML, and to
onitor them when transplanted in recipient mice. However, pre-
iminary results (unpublished data) suggests that early time points
fter exposure to ionising radiation, days or potentially longer, are
ot suitable since Sfpi1 is highly expressed due to repopulation of
he bone marrow after exposure. Instead we propose a good time
oint to use the model would be at the time when an expanding
lone of cells with interstitial chromosome 2 deletions are present
n the bone marrow at 12–15 months after exposure to ionising
adiation [13].
Although this model may  only imperfectly mimic  rAML in
umans and the described reporter gene approach requires
eﬁnement before it will be possible to investigate the fate of indi-
idual haematopoietic progenitors/stem cells that have acquired
ancer-associated chromosomal deletion Del2 within their nat-
ral microenvironment at an early stage of radiation-induced
eukaemia, our ﬁndings provide proof of principle that this ﬂuo-
escent reporter gene system is a viable approach for detecting,
numerating and studying Del2-bearing cells in their normal tis-
ue context. Heterozygous mutations of PU.1 have been found in
uman AML  cases [48]. Furthermore, the gene has also found to
e suppressed in some cases of promyelocytic leukaemia, both by
he promyelocytic leukaemia-retinoic acid receptor  (PML-RARA)
usion protein and mutations of upstream regulatory elements
49,50]. This study demonstrates that radiation-induced Del2 canrch 37 (2013) 1374– 1382 1381
be detected in live cancer cells and furthermore R235 type of point
mutations can sometimes be inferred. Hence, we  provided a useful
transgenic mouse experimental system to study radiation-induced
AML and mutations of PU.1 in general. To the best of our knowledge,
this has not been reported previously.
5. Conclusions
In conclusion, extension of the present reporter gene insertion
approach to the pre-malignant state (early after radiation-
exposure) should help to gain further understanding of the
mechanisms involved in IR-induced leukaemia processes. Follow-
ing isolation and transplantation, monitoring of these individual
pre-leukaemic cells and investigating their fate within their nat-
ural microenvironment should prove to be extremely useful in
dissecting the steps in tumour initiation, promotion and malig-
nant progression and could lead to new insights into the nature
of the molecular mechanisms and identiﬁcation of the cell of ori-
gin in radiation-induced leukaemia, that are relevant for human
leukaemia and cancer in general. In the future, this model may
also be valuable for preclinical evaluation of therapeutic agents for
myeloid leukaemia.
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